1. Home
  2. ACAD vs ATAT Comparison

ACAD vs ATAT Comparison

Compare ACAD & ATAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Atour Lifestyle Holdings Limited

ATAT

Atour Lifestyle Holdings Limited

N/A

Current Price

$38.19

Market Cap

4.3B

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
ATAT
Founded
1993
2013
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.3B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
ACAD
ATAT
Price
$17.18
$38.19
Analyst Decision
Buy
Strong Buy
Analyst Count
20
21
Target Price
$30.21
★ $49.47
AVG Volume (30 Days)
★ 2.4M
944.0K
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
★ 2.03%
EPS Growth
★ 69.12
N/A
EPS
★ 0.51
N/A
Revenue
★ $726,437,000.00
N/A
Revenue This Year
$19.55
$35.00
Revenue Next Year
$13.34
$18.64
P/E Ratio
$34.47
★ $26.11
Revenue Growth
★ 40.45
N/A
52 Week Low
$15.86
$30.07
52 Week High
$30.96
$43.17

Technical Indicators

Market Signals
Indicator
ACAD
ATAT
Relative Strength Index (RSI) 34.82 63.02
Support Level $15.86 $37.05
Resistance Level $22.71 $38.88
Average True Range (ATR) 1.20 1.28
MACD -0.11 0.29
Stochastic Oscillator 18.38 67.44

Price Performance

Historical Comparison
ACAD
ATAT

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About ATAT Atour Lifestyle Holdings Limited

Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.

Share on Social Networks: